You just read:

Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial

News provided by

Novo Nordisk

Jun 12, 2017, 17:15 ET